The Corrona Japan RA Registry has a target enrollment of approximately 2,000 subjects being prescribed for the first-time, a medication for RA from one of the following drug classes: Conventional DMARDs, JAK inihibitors, Anti-TNF biologic DMARDs, Non-TNF biologic DMARDs.